AZD2171 to Treat Prostate Cancer

NCT00436956 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

NIH

Sponsor class

Conditions

Prostate Cancer

Interventions

PROCEDURE: Magnetic Resonance Imaging (DCE-MRI)
DRUG: AZD2171
DRUG: Prednisone

Sponsor

National Cancer Institute (NCI)